Summary of COVID-19 atovaquone studies
Hide extended summaries
RCT 60 hospitalized COVID-19 patients showing no significant difference in viral clearance with atovaquone. Patients were randomized 2:1 to receive atovaquone 1500mg BID or placebo for up to 10 days, with both groups receiving standard of care treatments including remdesivir and dexamethasone. Pharmacokinetic data revealed that adequate inhibitory drug concentrations were likely not achieved in most patients by day 3, with higher BMI negatively correlating with drug levels. Authors observed an inverse correlation between atovaquone plasma concentration and viral load, suggesting a potential antiviral effect might be possible with adequate dosing.
Sep 2022, Frontiers in Pharmacology, https://www.frontiersin.org/articles/10.3389/fphar.2022.1020123/full, https://c19p.org/jain5
1. Jain et al., Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial
60 patient atovaquone late treatment RCT: 39% higher mortality (p=1), 20% greater improvement (p=0.56), and 16% shorter hospitalization (p=0.07).RCT 60 hospitalized COVID-19 patients showing no significant difference in viral clearance with atovaquone. Patients were randomized 2:1 to receive atovaquone 1500mg BID or placebo for up to 10 days, with both groups receiving standard of care treatments including remdesivir and dexamethasone. Pharmacokinetic data revealed that adequate inhibitory drug concentrations were likely not achieved in most patients by day 3, with higher BMI negatively correlating with drug levels. Authors observed an inverse correlation between atovaquone plasma concentration and viral load, suggesting a potential antiviral effect might be possible with adequate dosing.
Sep 2022, Frontiers in Pharmacology, https://www.frontiersin.org/articles/10.3389/fphar.2022.1020123/full, https://c19p.org/jain5
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.